ArticleTherapeutic advances in medical oncology2026
Gemcitabine/nab-paclitaxel plus S-1 combination compared with gemcitabine/nab-paclitaxel in advanced pancreatic ductal adenocarcinoma: a retrospective study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic adenocarcinoma is one of the leading causes of cancer-related mortality. The median overall survival (OS) of patients with advanced pancreatic ductal adenocarcinoma (PDAC) is less than 1 year. The recent phase III NAPOLI-3 study showed that triplet chemotherapy improved OS compared to the commonly used gemcitabine/nab-paclitaxel (GA) regimen. S-1 is widely used in Asia for the treatment of PDAC, and a combination strategy with S-1 has shown encouraging results in previous studies. Objectives: We aimed to determine whether the addition of S-1 to GA offers more benefits than GA alone as a first-line treatment for advanced PDAC. Design: This was a retrospective study of patients with advanced PDAC treated at the Taichung Veterans General Hospital, Taiwan. All patients received first-line GA-based therapy, including GA alone or GA in combination with S-1 (GAS). Methods: Retrospectively reviewed clinical characteristics and outcomes, including the objective response rate (ORR), progression-free survival (PFS), and OS, were compared between the two groups. Some patients underwent genetic testing using the FoundationOne CDx (Foundation Medicine). The effects of the treatment on major genetic alterations were also analyzed. Results: Between January 1, 2022, and February 10, 2025, 89 patients were enrolled. Among these, 45 and 44 underwent GA and GAS, respectively. The median follow-up time was 10.2 months. ORR was significantly higher in patients who received GAS than in those who did not (48% vs 18%, Conclusion: The S-1 could be combined with GA as another potential triplet combination treatment option for advanced PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.